Rapamycin (Sirolimus) – Kodiac biolabs

Plain-language summaryIntrigue 90 / 100

Rapamycin (sirolimus), sold as Rapamune, is a bacterial natural product originally used as an immunosuppressant after organ transplant. It inhibits the mTOR pathway, a master regulator of cell growth and aging. It is the most studied longevity intervention; Mikhail Blagosklonny’s hypothesis that intermittent rapamycin slows aging has driven extensive research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel frontier

81/100

The reference mTOR probe with the strongest pharmacological longevity evidence base in existence

Rapamycin is one of those compounds where the research arc keeps bending. Isolated in 1972 from an Easter Island soil sample, it spent decades as a transplant drug before the field realized it might be doing something far more interesting. The ITP data published in 2009 changed the conversation: genetically heterogeneous mice started on late treatment showed genuine lifespan extension, reproducible across three independent sites. That replication matters. Single-lab longevity claims are everywhere; multi-site ITP confirmation is rare, and rapamycin has it.

The mechanism is mTORC1 inhibition through FKBP12 binding, and what makes this compelling isn’t just the immunosuppression angle. mTOR sits at a genuine convergence point: nutrient sensing, autophagy flux, cellular senescence accumulation, ribosomal biogenesis, and downstream effects on age-related inflammation. When you inhibit mTORC1 appropriately, you’re essentially pulling one lever and hitting multiple aging hallmarks simultaneously. Thats the kind of mechanistic elegance that serious geroscience investigators care about.

What we like here is the bench utility. Rapamycin is the reference probe for mTOR biology. If you’re studying nutrient sensing, autophagy, senescence, cancer metabolism, or aging at the cellular level, you need rapamycin in your toolkit. There isn’t a cleaner or better-validated way to inhibit mTORC1. The rapalogs (everolimus, temsirolimus) exist but they’re downstream of rapamycin’s place in the literature and are mostly disease-specific derivatives. For research purposes, this is the compound.

The evidence base is unusually strong for a compound in this space. FDA approval for renal transplant means substantial human PK/PD data. The ITP multi-site replication puts the lifespan extension data above essentially anything else in the pharmacological longevity field. Human longevity-focused trials are underway, including the PEARL study and other geroscience protocols using intermittent dosing schedules to mitigate the immunosuppressive effects that complicate chronic daily administration.

Honestly, the main concern isn’t mechanism or evidence, it’s the mTORC2 question. Chronic dosing starts to affect mTORC2 in ways that can blunt some of the intended benefits, and there’s real debate about optimal dosing intervals in the longevity context. The intermittent dosing hypothesis is sensible mechanistically but not definitively proven in humans yet. That uncertainty is a legitimate open question, not a reason to deprioritize the compound. For investigators working on longevity biology, mTOR pathway signaling, senescence research, or metabolic aging, rapamycin isnt optional. It defines the field.

Novelty: 62
Mechanism promise: 85
In-category differentiation: 88
Evidence quality: 85
Translational signal: 82
Research bench value: 90

Rationale Rapamycin holds an unusual position: FDA-approved with massive clinical PK/PD data, AND the most replicated pharmacological longevity intervention on record via ITP multi-site confirmation. Novelty is constrained by the compound’s 50-year age, but its role as the irreplaceable mTOR probe, its central mechanism in aging biology, and an active clinical longevity research program justify high scores across mechanism, differentiation, evidence, and bench value.

mTOR inhibitor / immunosuppressant

A bacterial macrolide isolated from Streptomyces hygroscopicus, FDA-approved as an immunosuppressant and increasingly investigated for longevity applications through mTOR inhibition.

Abstract

Rapamycin (Sirolimus, Rapamune; CAS 53123-88-9; molecular formula C51H79NO13; molecular weight 914.17) is a macrolide compound isolated in 1972 from Streptomyces hygroscopicus from Easter Island (Rapa Nui, providing the name). The compound was approved by the FDA in 1999 as an immunosuppressant for renal transplantation. Mechanism is selective inhibition of mTORC1 (mammalian target of rapamycin complex 1) through binding to FKBP12 and forming a complex that allosterically inhibits mTOR kinase activity. Beyond immunosuppression, rapamycin extends lifespan in multiple model organisms (yeast, worms, flies, mice) when administered late in life, making it the most extensively documented pharmacological intervention for lifespan extension. The Interventions Testing Program (ITP) at NIA showed reproducible lifespan extension in genetically heterogeneous mice. Mechanisms of lifespan extension include reduced cellular senescence, improved autophagy, attenuation of age-related inflammation, and reduced age-related cancer incidence. The compound is increasingly used off-label for longevity applications by physicians and patients pursuing geroscience interventions; intermittent dosing schedules (5 to 10 mg weekly or monthly) are used to reduce immunosuppressive effects. Pharmacokinetics: plasma half-life 60 to 70 hours; high oral bioavailability; CYP3A4 metabolism.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-095Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.